All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 242 points (1.5%) at 16,127 as of Tuesday, Jan. 26, 2016, 11:55 AM ET. The NYSE advances/declines ratio sits at 2,449 issues advancing vs. 538 declining with 103 unchanged.

The Drugs industry currently sits down 0.8% versus the S&P 500, which is up 1.0%. On the negative front, top decliners within the industry include

Incyte

(

INCY

), down 4.7%,

Celgene

(

CELG

), down 1.1% and

Bristol-Myers Squibb Company

(

BMY

), down 0.7%. Top gainers within the industry include

GlaxoSmithKline

(

GSK

), up 2.3%,

Gilead

(

GILD

), up 1.4%,

Sanofi

(

SNY

), up 1.1%,

Merck

(

MRK

), up 0.9% and

AstraZeneca

(

AZN

), up 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Shire

(

SHPG

) is one of the companies pushing the Drugs industry lower today. As of noon trading, Shire is down $3.36 (-1.9%) to $177.45 on average volume. Thus far, 596,751 shares of Shire exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $176.63-$179.62 after having opened the day at $179.20 as compared to the previous trading day's close of $180.81.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. Shire has a market cap of $36.5 billion and is part of the health care sector. Shares are down 11.8% year-to-date as of the close of trading on Monday. Currently there are 10 analysts that rate Shire a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Recommends

TheStreet Ratings rates

Shire

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Shire Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Illumina

(

ILMN

) is down $4.13 (-2.4%) to $170.35 on light volume. Thus far, 422,319 shares of Illumina exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $168.68-$175.29 after having opened the day at $175.29 as compared to the previous trading day's close of $174.48.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $25.9 billion and is part of the health care sector. Shares are down 9.1% year-to-date as of the close of trading on Monday. Currently there are 10 analysts that rate Illumina a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates

Illumina

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Illumina Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Regeneron Pharmaceuticals

(

REGN

) is down $9.72 (-2.0%) to $463.40 on light volume. Thus far, 251,161 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 773,400 shares. The stock has ranged in price between $456.25-$474.40 after having opened the day at $474.32 as compared to the previous trading day's close of $473.12.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Regeneron Pharmaceuticals has a market cap of $49.3 billion and is part of the health care sector. Shares are down 12.8% year-to-date as of the close of trading on Monday. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Regeneron Pharmaceuticals

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, good cash flow from operations and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Regeneron Pharmaceuticals Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).